Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Navstel
- Development stage
- Phase 3
- Lead developer
- Alcon
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Navstel, also known as Next Generation Ophthalmic Irrigating Solution (NGOIS), is an intraocular irrigating solution developed by Alcon. It is a balanced salt solution (BSS) enriched with 0.015% hypromellose (HPMC), a viscoelastic polymer. Navstel is indicated for use during intraocular surgical procedures, such as cataract extraction and intraocular lens (IOL) implantation. The addition of hypromellose provides enhanced protection to the corneal endothelium by coating the tissue and reducing mechanical trauma and oxidative stress during surgery. It also helps maintain the structural integrity and volume of the anterior chamber. The product was approved by the FDA in 2008 (NDA 022193).
- Brand names
- Navstel
- Other names
- Next Generation Ophthalmic Irrigating Solution
Beyond the preview
Go deeper on Navstel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Navstel.